Global Anxiety Disorders and Depression Treatment Market Set to Reach $34.31 Billion by 2033, Driven by Rising Mental Health Awareness, Digital Therapeutics, and Pharmacological Innovations
ByAinvest
Tuesday, Sep 9, 2025 1:28 pm ET2min read
LLY--
Analysts expect Eli Lilly to post earnings of $6.42 per share in its upcoming earnings disclosure, representing a year-over-year growth of 444.07%. The consensus estimate forecasts revenue to be $16.05 billion, indicating a 40.32% growth compared to the prior year [1].
For the full year, the Zacks Consensus Estimates project earnings of $23.03 per share and revenue of $61.81 billion, representing changes of +77.29% and +37.22%, respectively, from the prior year [1]. Eli Lilly currently holds a Zacks Rank of #3 (Hold), indicating a neutral outlook [1].
Valuation metrics show that Eli Lilly is being traded at a Forward P/E ratio of 31.58, which is a premium compared to the industry average of 14.41. The PEG ratio of 1.02 is also slightly lower than the industry average of 1.37 [1].
The Large Cap Pharmaceuticals industry, which includes Eli Lilly, is part of the Medical sector. This industry ranks 160 out of 250+ industries, placing it in the bottom 36% [1].
The Anxiety Disorders and Depression Treatment Market, a key area for Eli Lilly, is expected to grow from $20.51 billion in 2024 to $34.31 billion by 2033, driven by rising mental health awareness, global stress levels, and advancements in therapies. Increased adoption of digital therapeutics and telemedicine is enhancing access and reducing stigma, with notable interventions such as India’s Tele MANAS offering nationwide psychiatric services .
Key players like Pfizer, Johnson & Johnson, and Eli Lilly continue to drive market innovations, with Eli Lilly's focus on therapies like Trintellix and Vyepti. These advancements, coupled with the company's strong earnings growth and expanding customer base, position Eli Lilly well to capitalize on the growing market for anxiety and depression treatments.
References:
[1] https://www.nasdaq.com/articles/eli-lilly-lly-laps-stock-market-heres-why
The Anxiety Disorders and Depression Treatment Market is expected to grow from $20.51 billion in 2024 to $34.31 billion by 2033, driven by rising mental health awareness, global stress levels, and advancements in therapies. Increased adoption of digital therapeutics and telemedicine is enhancing access and reducing stigma, with notable interventions such as India’s Tele MANAS offering nationwide psychiatric services. Key players like Pfizer, Johnson & Johnson, and Eli Lilly continue to drive market innovations.
The Anxiety Disorders and Depression Treatment Market is expected to grow from $20.51 billion in 2024 to $34.31 billion by 2033, driven by rising mental health awareness, global stress levels, and advancements in therapies. Increased adoption of digital therapeutics and telemedicine is enhancing access and reducing stigma, with notable interventions such as India’s Tele MANAS offering nationwide psychiatric services. Key players like Pfizer, Johnson & Johnson, and Eli Lilly continue to drive market innovations.
Eli Lilly (LLY) saw its stock rise by 1.51% to $738.17 in the latest trading session, outpacing the S&P 500's gain of 0.21% [1]. Over the past month, shares of the drugmaker have appreciated by 16.23%, outperforming the Medical sector's gain of 5.47% and the S&P 500's gain of 3.07% [1].Analysts expect Eli Lilly to post earnings of $6.42 per share in its upcoming earnings disclosure, representing a year-over-year growth of 444.07%. The consensus estimate forecasts revenue to be $16.05 billion, indicating a 40.32% growth compared to the prior year [1].
For the full year, the Zacks Consensus Estimates project earnings of $23.03 per share and revenue of $61.81 billion, representing changes of +77.29% and +37.22%, respectively, from the prior year [1]. Eli Lilly currently holds a Zacks Rank of #3 (Hold), indicating a neutral outlook [1].
Valuation metrics show that Eli Lilly is being traded at a Forward P/E ratio of 31.58, which is a premium compared to the industry average of 14.41. The PEG ratio of 1.02 is also slightly lower than the industry average of 1.37 [1].
The Large Cap Pharmaceuticals industry, which includes Eli Lilly, is part of the Medical sector. This industry ranks 160 out of 250+ industries, placing it in the bottom 36% [1].
The Anxiety Disorders and Depression Treatment Market, a key area for Eli Lilly, is expected to grow from $20.51 billion in 2024 to $34.31 billion by 2033, driven by rising mental health awareness, global stress levels, and advancements in therapies. Increased adoption of digital therapeutics and telemedicine is enhancing access and reducing stigma, with notable interventions such as India’s Tele MANAS offering nationwide psychiatric services .
Key players like Pfizer, Johnson & Johnson, and Eli Lilly continue to drive market innovations, with Eli Lilly's focus on therapies like Trintellix and Vyepti. These advancements, coupled with the company's strong earnings growth and expanding customer base, position Eli Lilly well to capitalize on the growing market for anxiety and depression treatments.
References:
[1] https://www.nasdaq.com/articles/eli-lilly-lly-laps-stock-market-heres-why
The Anxiety Disorders and Depression Treatment Market is expected to grow from $20.51 billion in 2024 to $34.31 billion by 2033, driven by rising mental health awareness, global stress levels, and advancements in therapies. Increased adoption of digital therapeutics and telemedicine is enhancing access and reducing stigma, with notable interventions such as India’s Tele MANAS offering nationwide psychiatric services. Key players like Pfizer, Johnson & Johnson, and Eli Lilly continue to drive market innovations.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet